Kestra Medical Technologies, Ltd. (KMTS) Reports Q3 Loss of $0.50, provides guidance

Kestra Medical Technologies, Ltd. (NASDAQ: KMTS) reported Q3 EPS of ($0.50). Revenue for the quarter came in at $19.4 million.

Fiscal Year 2026 Revenue Guidance
Kestra is increasing its FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. This compares to prior FY26 revenue guidance of $85 million.

For earnings history and earnings-related data on Kestra Medical Technologies, Ltd. (KMTS) click here.

You May Also Be Interested In

• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• Globalstar confirms launch of 8 HIBLEO-4 replacement satellites